Affymetrix Inc. of Santa Clara, Calif.,
has given nonexclusive access to Epigenomics AG of Berlin for its microarray technology.
With this agreement, the German company will be able to develop and market microarray-based
in vitro diagnostic tests for cancer and other diseases using Affymetrix’s
DNA methylation methods.
MORE FROM PHOTONICS MEDIA